Khan SU, et al. - This study was designed to test a hypothesis that the superiority of oral anticoagulant (OAC) plus dual antiplatelet therapy (DAPT) in patients with atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is mainly endorsed by observational studies, while on the contrary, randomized clinical trials (RCTs) have suggested that OAC plus single antiplatelet agent (SAP) is safer and equally effective approach. Researchers found that observational data demonstrated similar safety and reduced risk of myocardial infarction (MI) with OAC plus DAPT. Opposed to this, OAC plus SAP was recommended in randomized data for better safety and equal efficacy compared to OAC plus DAPT.